DDrare: Database of Drug Development for Rare Diseases

Losartan and other angiotensin receptor blockers (DrugBank: Losartan, Angiotensin)

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00446862 (ClinicalTrials.gov)	March 2007	11/3/2007	The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study	Fabry Disease;Proteinuria	Drug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers	University of Alabama at Birmingham	NULL	Completed	19 Years	85 Years	Both	36	N/A	United States;Slovenia;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00446862
(ClinicalTrials.gov)

March 2007

11/3/2007

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study

Fabry Disease;Proteinuria

Drug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers

University of Alabama at Birmingham

NULL

Completed

19 Years

85 Years

Both

N/A

United States;Slovenia;Germany